Modular Medical, Inc. (MODD) Gets Positive ISO 13485 Decision Toward Certification

Modular Medical (MODD) received a positive ISO 13485:2016 decision, a step toward certification. The company aims for a 2027 CE Mark submission for its Pivot tubeless patch pump under EU MDR. This milestone supports its EU launch plan, with certification and CE Mark expected to enable distribution and revenue.

Original reporting
Published Oct 27, 2026, 3:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 3:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Modular Medical, Inc. (MODD) Gets Positive ISO 13485 Decision Toward Certification — source image
Decision brief

The 30-second read

$MODDBullishMed
01

Why it matters

The ISO 13485 decision is a prerequisite for CE Mark, unlocking EU distribution and revenue streams.

02

Market read

Regulatory clearance could drive near‑term price appreciation for MODD as EU launch becomes feasible.

03

What to watch

Potential competition from established pump manufacturers and reimbursement uncertainties in Europe.

Relevance 6/10Novelty 7/10Timing: after-hours

Background

Modular Medical is targeting a 2027 CE Mark submission for its Pivot tubeless patch pump under EU MDR.

Company-level read

Ticker impact

$MODDBullishHigh confidence
Context

Modular Medical received a positive notified body decision toward ISO 13485 certification, a key step toward EU CE Mark for its Pivot pump.

Expected impact

potential upside as investors price in EU market entry

Evidence & confidence

Regulatory approval is a material catalyst for a micro‑cap medical device firm.

Market effects

May boost sentiment for EU‑focused med‑tech and device companies awaiting regulatory clearance.

Could positively affect European medical device market sentiment.

Limited to niche med‑tech sector, but highlights regulatory pathways for similar firms.

Counterpoint

If EU approval delays or market uptake is slower than expected, the catalyst could be overstated.

Key entities

  • Modular Medical, Inc.

    Medical device maker developing the Pivot pump.

Related articles

$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

$AMZNHigh

Data Center Backlash Hits Amazon Hardest in Ohio

Amazon's $17B Ohio data center plan is at risk after voters approved measures to limit development, affecting 3 projects and 1.8GW of power. Amazon shares rose 0.43% premarket. The company plans $23B investment in Ohio by 2030, with most capital spending going to AI infrastructure, according to the Financial Times and Regbase data.

$SMCIMed

Wife of Senior Nvidia Executive Caught Up in Alleged AI Chip Smuggling Scandal

U.S. prosecutors charged three individuals tied to Super Micro Computer with allegedly smuggling $2.5B in AI servers to China, violating export controls. Super Micro's servers use Nvidia GPUs, placing it in the supply chain under U.S. scrutiny. A shareholder lawsuit alleges former exec Cenly Chen knew of illicit sales, which the company denies. Short-seller Muddy Waters raised questions about Chen's ties to an Nvidia executive, but no criminal charges have been filed against either.